Article Data

  • Views 496
  • Dowloads 161

Original Research

Open Access

Evaluation of the relationship of the amount of ascites as measured quantitatively using computed tomography with chemotherapy toxicity in patients with ovarian cancer

  • Duygu Bayir Garbioglu1,*,
  • Elif Gundogdu2
  • Nazan Demir3
  • Murat Dincer4

1Department of Medical Oncology, Faculty of Medicine, Bulent Ecevit University, 67020 Zonguldak, Turkey

2Department of Radiology, Faculty of Medicine, Eskisehir Osmangazi University, 26010 Eskisehir, Turkey

3Sultan Murat 1st State Hospital, Medical Oncology, 22020 Edirne, Turkey

4Department of Medical Oncology, Faculty of Medicine, Eskisehir Osmangazi University, 26010 Eskisehir, Turkey

DOI: 10.22514/ejgo.2023.078 Vol.44,Issue 5,October 2023 pp.46-54

Submitted: 21 February 2023 Accepted: 05 May 2023

Published: 15 October 2023

*Corresponding Author(s): Duygu Bayir Garbioglu E-mail:


In this study, it was planned to investigate the effects of ascites and sarcopenia on treatment toxicity, disease free survival (DFS) and disease specific survival (DSS) times in a population of patients with stage 3–4 ovarian cancer. In this retrospective study that include 80 patients treated and followed-up for advanced stage ovarian cancer in a university hospital between 2012–2019, ascites volumes and sarcopenia indices of the patients were calculated by computed tomography from medical patient records, and their clinico-pathologic characteristics as well as laboratory variables were reviewed. The median survival was 30.10 ± 2.85 months for the patients with ascites and 54.26 ± 4.16 months without ascites (p < 0.001). The duration of DSS was found to be negatively affected in patients with ascites (Hazard Ratio (HR): 3.048), prognostic nutritional index (PNI) <47.5 (HR: 2.528), platelet (PLT) >338,000 (HR: 1.936), lactate dehydrogenase (LDH) value >320 (HR: 1.624), albumin value <4 (HR: 1.849). When factors that are found to have a significant relationship with DSS were assessed according to multivariate Cox regression analysis, the presence of ascites was identified as an independent risk factor associated with DSS (p: 0.004). The risk of developing grade 2 or 3 neutropenia, anemia and thrombocytopenia is significantly increased following the first chemotherapy course in patients with ascites when compared to those without ascites (p: 0.006). The presence of ascites in patients with ovarian cancer is a risk factor associated with chemotherapy toxicity and reduced survival.


Ascites; Chemotherapy toxiticy; Ovarian cancer; Sarcopenia

Cite and Share

Duygu Bayir Garbioglu,Elif Gundogdu,Nazan Demir,Murat Dincer. Evaluation of the relationship of the amount of ascites as measured quantitatively using computed tomography with chemotherapy toxicity in patients with ovarian cancer. European Journal of Gynaecological Oncology. 2023. 44(5);46-54.


[1] Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA: A Cancer Journal for Clinicians. 2021; 71: 7–33.

[2] Jiang R, Zhu J, Kim JW, Liu J, Kato K, Kim HS, et al. Study of upfront surgery versus neoadjuvant chemotherapy followed by interval debulking surgery for patients with stage IIIC and IV ovarian cancer, SGOG SUNNY (SOC-2) trial concept. Journal of Gynecologic Oncology. 2020; 31: e86.

[3] Ni J, Zhang L. Cancer cachexia: definition, staging, and emerging treatments. Cancer Management and Research. 2020; 12: 5597–5605.

[4] Anjanappa M, Corden M, Green A, Roberts D, Hoskin P, McWilliam A, et al. Sarcopenia in cancer: risking more than muscle loss. Technical Innovations & Patient Support in Radiation Oncology. 2020; 16: 50–57.

[5] Ford CE, Werner B, Hacker NF, Warton K. The untapped potential of ascites in ovarian cancer research and treatment. British Journal of Cancer. 2020; 123: 9–16.

[6] Oriuchi N, Nakajima T, Mochiki E, Takeyoshi I, Kanuma T, Endo K, et al. A new, accurate and conventional five-point method for quantitative evaluation of ascites using plain computed tomography in cancer patients. Japanese Journal of Clinical Oncology. 2005; 35: 386–390.

[7] Ubachs J, Ziemons J, Minis‐Rutten IJG, Kruitwagen RFPM, Kleijnen J, Lambrechts S, et al. Sarcopenia and ovarian cancer survival: a systematic review and meta‐analysis. Journal of Cachexia, Sarcopenia and Muscle. 2019; 10: 1165–1174.

[8] Weir CB, Jan A. BMI classification percentile and cut off points. StatPearls Publishing: Treasure Island (FL). 2021.

[9] Arshad U, Taubert M, Seeger-Nukpezah T, Ullah S, Spindeldreier KC, Jaehde U, et al. Evaluation of body-surface-area adjusted dosing of high-dose methotrexate by population pharmacokinetics in a large cohort of cancer patients. BMC cancer. 2021; 21: 719.

[10] Feng Z, Wen H, Ju X, Bi R, Chen X, Yang W, et al. The preoperative prognostic nutritional index is a predictive and prognostic factor of high-grade serous ovarian cancer. BMC Cancer. 2018; 18: 883.

[11] Eisenhauer EA TP, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). European Journal of Cancer. 2009; 45: 228–247.

[12] Pin F, Couch ME, Bonetto A. Preservation of muscle mass as a strategy to reduce the toxic effects of cancer chemotherapy on body composition. Current Opinion in Supportive & Palliative Care. 2018; 12: 420–426.

[13] Purcell SA, Kok DE, Ketterl T, Garcia MB, Joffe L, Brown JC, et al. Pharmacokinetics of cancer therapeutics and energy balance: the role of diet intake, energy expenditure, and body composition. JNCI Monographs. 2023; 2023: 3–11.

[14] Saygili U, Guclu S, Uslu T, Erten O, Dogan E. The effect of ascites, mass volume, and peritoneal carcinomatosis on serum CA125 levels in patients with ovarian carcinoma. International Journal of Gynecological Cancer. 2002; 12: 438–442.

[15] Ayhan A, Gultekin M, Taskiran C, Dursun P, Firat P, Bozdag G, et al. Ascites and epithelial ovarian cancers: a reappraisal with respect to different aspects. International Journal of Gynecologic Cancer. 2007; 17: 68–75.

[16] Quan Q, Zhou S, Liu Y, Yin W, Liao Q, Ren S, et al. Relationship between ascites volume and clinical outcomes in epithelial ovarian cancer. Journal of Obstetrics and Gynaecology Research. 2021; 47: 1527–1535.

[17] Feigenberg T, Clarke B, Virtanen C, Plotkin A, Letarte M, Rosen B, et al. Molecular profiling and clinical outcome of high-grade serous ovarian cancer presenting with low- versus high-volume ascites. BioMed Research International. 2014; 2014: 367103.

[18] Anjanappa M, Corden M, Green A, Roberts D, Hoskin P, McWilliam A, et al. Sarcopenia in cancer: risking more than muscle loss. Technical Innovations & Patient Support in Radiation Oncology. 2020; 16: 50–57.

[19] Allanson ER, Peng Y, Choi A, Hayes S, Janda M, Obermair A. A systematic review and meta-analysis of sarcopenia as a prognostic factor in gynecological malignancy. International Journal of Gynecologic Cancer. 2020; 30: 1791–1797.

[20] Bruno KDA, Sobreira da Silva MJ, Chaves GV. Association of body composition with toxicity to first-line chemotherapy and three-year survival in women with ovarian adenocarcinoma. Acta Oncologica. 2021; 60: 1611–1620.

[21] Staley SA, Tucker K, Newton M, Ertel M, Oldan J, Doherty I, et al. Sarcopenia as a predictor of survival and chemotoxicity in patients with epithelial ovarian cancer receiving platinum and taxane-based chemotherapy. Gynecologic Oncology. 2020; 156: 695–700.

[22] Del Grande M, Rizzo S, Nicolino GM, Colombo I, Rossi L, Manganaro L, et al. Computed tomography-based body composition in patients with ovarian cancer: association with chemotoxicity and prognosis. Frontiers in Oncology. 2021; 11: 718815.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time